Immune checkpoint inhibitors and BRAF/MEK inhibitors are the cornerstone of treatment for melanoma; however, primary and acquired resistance to these therapies highlight an ongoing, unmet need to develop novel treatment modalities. This evidence concerns the gene MAP2K7 and melanoma.